ESTRO 2024 - Abstract Book

S2256

Clinical - Upper GI

ESTRO 2024

96% of patients experienced some kind of acute toxicity during or immediately after treatment with pain, dysphagia/esophagitis, and fatigue being the most common. Most side effects were handled with medication, but approximately 1/3 were hospitalized during treatment due to toxicity. 1 patients died due to grade 5 acute toxicity (infection). Late side effects were not systematically recorded; the most common were pain, fatigue and dysphagia with 12% treated with dilatation and 7% receiving a stent.

Conclusion:

In conclusion, overall survival among patients treated with neo-adjuvant or definitive chemo-RT for oesophageal cancer is acceptable though still discouraging. The majority of patients treated with neo-adjuvant chemo-RT reached surgery. Treatment side effects are frequent and largely manageable, but the occurrence of late side effects in this study is presumably underreported.

Dosimetric data awaits further examination.

Keywords: esophageal cancer, survival, morbidity

2609

Digital Poster

Towards a more robust proton beam arrangement against diaphragm changes for esophageal cancer

Gloria Vilches-Freixas, Kim van der Klugt, Kim de Laat, Jeroen Buijsen, Richard Canters, Maaike Berbee